Mike Sheikh

#NextelMedical $MAJI. #Bioxytran $BIXT Filer @AF_Academy Grad & Pilot ExBroker @MorganStanley. #BiotechAnalyst Expert in #Galectin research #cancer #MASH #GBM

[Mike Sheikh @MikeSheikh2]

Blown away by the @ExousiaBio $LMMY $MAJI Projenicyte JV presentation #REMIJPM How can u not be excited about this potential #GBM treatment going through the regulatory process. Pay attention to the beginning. Replay it a couple of times. Let it sink in. Let’s get some engagement. #JPM2026 #biotechshowcase #Glioblastoma

[NextTel Medical Corp @NexTelMedical]

$MAJI - Here is an interview done by the former CEO Mike Sheikh at the Roth Conference in San Diego, earlier this year.
https://t.co/gLS14rv67N

[Hil Davis @Hil_Davis]

$DBGI Seems to be a disconnect in valuation, especially given recent news and guidance. As we stated in our PR there is significant revenue growth, transitioning to CF + and now three major channels of growth. Positive company updates to come because momentum begets momentum

[Hil Davis @Hil_Davis]

$DBGI https://t.co/2SxCKZIS1h

[Mike Sheikh @MikeSheikh2]

@MicroCapTweets @buffalofireside Thank you for highlighting this. Now annualize it.

[NextTel Medical Corp @NexTelMedical]

NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization https://t.co/ffA5Owe2eI

[Hil Davis @Hil_Davis]

$DBGI Digital Brands Group Receives Initial Orders for $125M U.S. Program https://t.co/VyOWw3mQw3

[NextTel Medical Corp @NexTelMedical]

$MAJI is thrilled to announce that the two Definitive Acquisition Agreements have officially been executed. This marks a monumental milestone in our growth strategy and a major step forward for shareholder value.
Key Next Steps:

OTC Market Filing: The Supplemental Information filing will be uploaded to the OTC platform in a timely manner.

Official Press Release: A formal PR detailing the transaction will be issued concurrently.

Shareholder Update: We are coordinating with @buffalofireside for an upcoming segment. Our CEO, along with the founder of both entities, will provide a comprehensive update on our combined vision, anticipated revenue, growth challenges, and the roadmap ahead.

We are incredibly excited about this new chapter and look forward to delivering sustained growth for our shareholders...More to come!

[Mike Sheikh @MikeSheikh2]

The T-Cells represent you immune surveillance & so many ppl got #COVID19 which is a disease that can suppress them. Think about all the diseases your T-cells can fight off too. So this news is not surprising at all. The question is what do we do about it.
1 Boost our T-cells
2 Try not to get sick anymore
3 Do both

[Mike Sheikh @MikeSheikh2]

@thommic The fact that $DBGI are getting international retailers who want to use their branding protection technology is a sign that the market price isn't reflecting the stocks true value. This is really is a nobrainer at this level.

[NextTel Medical Corp @NexTelMedical]

MAJI is pleased to announce that we have received and reviewed comments to the Definitive Agreements from our acquisition targets. The requested revisions have been forwarded to counsel for incorporation, and we anticipate fully executed Agreements for the first two acquisitions within the next 10 days. Additional updates to follow as we continue to advance our growth strategy.

[NextTel Medical Corp @NexTelMedical]

Huge update, $MAJI - Following our latest issuance, we are officially PAUSING all further Reg A sales! We want to give the market room to breathe, regroup, while we do the work on the business side to support an increased value. A massive thank you to our incredible shareholders who stepped up and backed us during this phase. We appreciate you more than you know!

[NextTel Medical Corp @NexTelMedical]

https://t.co/zFTkf22vQV

[NextTel Medical Corp @NexTelMedical]

Exciting milestones at $MAJI! We are significantly strengthening our financial position by reducing total liabilities by nearly $250,000 for the upcoming quarter. This follows a strategic renegotiation of terms for $LMMY’s cancer therapy loading tech.  We are also expanding our clinical footprint through a pending new acquisition focused on psilocybin exosomes for TBI and Frontotemporal Lobe. With an Orphan Drug Designation (ODD) application submitted, We are committed to delivering breakthrough solutions for complex brain trauma.

[Mike Sheikh @MikeSheikh2]

@Av8rLady @DrMakaryFDA @ProudMomGrammy @ImmunityBio @DrPatrick Its really good news BTW did you see this article that mentions $IBRX $RVMD https://t.co/qziRkGYii8

[Mike Sheikh @MikeSheikh2]

@DrMakaryFDA Great for $RVMD and #pancreaticcancer patients. When you present real evidence of safety and efficacy this FDA doesn't feel shy about helping #cancer patients in need. Great for #EAP Expanded Access Patients.

[NotTheMoma @NotTheMoma2]

$IFUS The news is out. Huge news. Time to load the boat, keel haul the shorts to hell. https://t.co/F16gBJkgBD
@MikeSheikh2 @realsheepwolf @unusual_whales

[Mike Sheikh @MikeSheikh2]

Breaking News - #Drone Market should benefit from the $75B #DOW budget. Some of these names should benefit. $ZENA $RCAT $DPRO $ONDS $AVAV $UMAC $AMPX

https://t.co/YbCNWIUkZa

[Mike Sheikh @MikeSheikh2]

$CAPR has an excellent risk to reward profile. Its highly derisked. Its superior to $SRPT for #DMD w/o those side effects & treatments in the pipeline from $RGNX $PTCT $SLDB $DYN. Excited about their #exosomal pipeline. Aug #PDUFA date could be a rising tide for all #exosome drug development companies. Put $JAZZ $MAJI $LMMY on your watchlists.https://t.co/OlzrZCQhgk

[Mike Sheikh @MikeSheikh2]

#cancer misdiagnosis like this happens all the time. This is why early screening tests that actually work are so important. Doctors are on a hunt for a test that truly tells if you have cancer before its a big untreatable lump. Key research is pointing us toward biomarkers associated w/ Cancer Stem Cells (CSCs)

[Mike Sheikh @MikeSheikh2]

When this #FDA reclassification of peptides goes into effect, the demand for telehealth services will increase. $HIMS a bellweather reacted positively and was looking to expand access of its existing offerings. While this move is in its infancy – it’s very clear that this is a boon for the sector in general. $MAJI looks forward to being part of the solution & is working hard to close 3 telehealth businesses. The FDA move to lower the bar of access to this category of drugs is a very positive development for the market. Nice to have @RobertKennedyJr backing their accessibility.

https://t.co/jhrULXqX2o